2026 Q3 - tulosraportti
19 päivää sitten
‧1 t 1 min
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä |
|---|---|---|
| 24 | ||
| 12 | ||
| 21 | ||
| 128 | ||
| 54 |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
NimiOsuus
Evli Ruotsi Pienyhtiöt B
2,79%Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q4 - tulosraportti 28.1.2027 |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q3 - tulosraportti 22.10. | ||
2026 Q2 - tulosraportti 14.7. | ||
2026 Q1 - tulosraportti 24.4. | ||
2025 Q4 - tulosraportti 27.1. | ||
2025 Q3 - tulosraportti 23.10.2025 |
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
·22.10.Earnings comment: Xvivo Perfusion 32% organic growth, even though there were easy comparison figures and some one-off items. Overall a completely OK report. The most interesting thing right now is products related to heart transplantations. Read more 👇 https://murgata.se/xvivo-perfusion-rapportkommentar-q3-2026/
·22.10.Better than all estimates, and positive opportunities for the coming quarters. Still slightly down. The market is not always easy to understand..How does it work? Have never understood. Just pure stock manipulation then? Isn't the risk just moved from one short seller to another.
·13.10.Xvivo – testing the long support line Xvivo has since the autumn of 2025 been moving in a large triangle with an ascending support line at the bottom and a slightly ascending resistance up around 310-320. The top came in August around 315, and since then it has gone quite hard downwards, approx. 33%. Now we are around 212, and it is precisely there that the ascending support line lies on both the weekly and daily chart. The weekly chart is now heavily oversold, and several of my indicators are right down at the bottom and are slowly starting to turn. On the daily chart, they have already started to turn up. Last time we saw the same picture on the line, in the spring, the stock ran from approx. 180 all the way up to 300. The company Xvivo makes machines and solutions for preserving organs during transplantation, and the business is actually running strong. In Q2, organic growth was 36%, and sales in thorax increased 53%. Over 600 patients have now been transplanted with their heart technology, and in Australia it is already used for approx. 40% of heart transplantations. The big hurdle is the approval of the heart product, especially in the US, where most of the investments go to precisely that process. If it gets through, it is a significant game changer for the company. Next financial report comes on October 22, and we will hear how far they are with the approvals. My setup Price now: approx. 213 Support: the ascending trend line, approx. 205-210 1st target: approx. 245 = approx. +15% 2nd target: approx. 285 = approx. +34% Longer term: the top line around 315 = approx. +48% Next major event: the Q3 report on October 22 If the support is broken: if we close below the line on a weekly basis, the triangle is broken downwards, and then you should not stand around hoping. If the support holds up towards the report, I think risk/reward looks really exciting. It is a medtech stock, so the report and news about approvals can give large fluctuations both ways. REMEMBER: The Q3 report on October 22 This is not investment advice, but my own technical assessment. Always do your own analysis.- ·1.10.Will the CEO's positive outlook on underlying growth from the Q2 report be scrutinized in Q3, which is released on 22/10? And have orders started being placed since the CE cert. for heart preservation technology on 11/8? If these points are met, I believe Xvivo will enter a strong period. What are your thoughts/perceptions on the near future?
I have just increased by 250 pcs more (50% extra) so am lying with 750 GAK 185 - so now it is welcome to go towards 300-400 pieces :-). Hope Danske has right about a strong Q3
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Dataa ei löytynyt
2026 Q3 - tulosraportti
19 päivää sitten
‧1 t 1 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·22.10.Earnings comment: Xvivo Perfusion 32% organic growth, even though there were easy comparison figures and some one-off items. Overall a completely OK report. The most interesting thing right now is products related to heart transplantations. Read more 👇 https://murgata.se/xvivo-perfusion-rapportkommentar-q3-2026/
- ·22.10.Better than all estimates, and positive opportunities for the coming quarters. Still slightly down. The market is not always easy to understand..How does it work? Have never understood. Just pure stock manipulation then? Isn't the risk just moved from one short seller to another.
- ·13.10.Xvivo – testing the long support line Xvivo has since the autumn of 2025 been moving in a large triangle with an ascending support line at the bottom and a slightly ascending resistance up around 310-320. The top came in August around 315, and since then it has gone quite hard downwards, approx. 33%. Now we are around 212, and it is precisely there that the ascending support line lies on both the weekly and daily chart. The weekly chart is now heavily oversold, and several of my indicators are right down at the bottom and are slowly starting to turn. On the daily chart, they have already started to turn up. Last time we saw the same picture on the line, in the spring, the stock ran from approx. 180 all the way up to 300. The company Xvivo makes machines and solutions for preserving organs during transplantation, and the business is actually running strong. In Q2, organic growth was 36%, and sales in thorax increased 53%. Over 600 patients have now been transplanted with their heart technology, and in Australia it is already used for approx. 40% of heart transplantations. The big hurdle is the approval of the heart product, especially in the US, where most of the investments go to precisely that process. If it gets through, it is a significant game changer for the company. Next financial report comes on October 22, and we will hear how far they are with the approvals. My setup Price now: approx. 213 Support: the ascending trend line, approx. 205-210 1st target: approx. 245 = approx. +15% 2nd target: approx. 285 = approx. +34% Longer term: the top line around 315 = approx. +48% Next major event: the Q3 report on October 22 If the support is broken: if we close below the line on a weekly basis, the triangle is broken downwards, and then you should not stand around hoping. If the support holds up towards the report, I think risk/reward looks really exciting. It is a medtech stock, so the report and news about approvals can give large fluctuations both ways. REMEMBER: The Q3 report on October 22 This is not investment advice, but my own technical assessment. Always do your own analysis.
- ·1.10.Will the CEO's positive outlook on underlying growth from the Q2 report be scrutinized in Q3, which is released on 22/10? And have orders started being placed since the CE cert. for heart preservation technology on 11/8? If these points are met, I believe Xvivo will enter a strong period. What are your thoughts/perceptions on the near future?I have just increased by 250 pcs more (50% extra) so am lying with 750 GAK 185 - so now it is welcome to go towards 300-400 pieces :-). Hope Danske has right about a strong Q3
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä |
|---|---|---|
| 24 | ||
| 12 | ||
| 21 | ||
| 128 | ||
| 54 |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
NimiOsuus
Evli Ruotsi Pienyhtiöt B
2,79%Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q4 - tulosraportti 28.1.2027 |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q3 - tulosraportti 22.10. | ||
2026 Q2 - tulosraportti 14.7. | ||
2026 Q1 - tulosraportti 24.4. | ||
2025 Q4 - tulosraportti 27.1. | ||
2025 Q3 - tulosraportti 23.10.2025 |
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Dataa ei löytynyt
2026 Q3 - tulosraportti
19 päivää sitten
‧1 t 1 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q4 - tulosraportti 28.1.2027 |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q3 - tulosraportti 22.10. | ||
2026 Q2 - tulosraportti 14.7. | ||
2026 Q1 - tulosraportti 24.4. | ||
2025 Q4 - tulosraportti 27.1. | ||
2025 Q3 - tulosraportti 23.10.2025 |
Tuotteita joiden kohde-etuutena tämä arvopaperi
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·22.10.Earnings comment: Xvivo Perfusion 32% organic growth, even though there were easy comparison figures and some one-off items. Overall a completely OK report. The most interesting thing right now is products related to heart transplantations. Read more 👇 https://murgata.se/xvivo-perfusion-rapportkommentar-q3-2026/
- ·22.10.Better than all estimates, and positive opportunities for the coming quarters. Still slightly down. The market is not always easy to understand..How does it work? Have never understood. Just pure stock manipulation then? Isn't the risk just moved from one short seller to another.
- ·13.10.Xvivo – testing the long support line Xvivo has since the autumn of 2025 been moving in a large triangle with an ascending support line at the bottom and a slightly ascending resistance up around 310-320. The top came in August around 315, and since then it has gone quite hard downwards, approx. 33%. Now we are around 212, and it is precisely there that the ascending support line lies on both the weekly and daily chart. The weekly chart is now heavily oversold, and several of my indicators are right down at the bottom and are slowly starting to turn. On the daily chart, they have already started to turn up. Last time we saw the same picture on the line, in the spring, the stock ran from approx. 180 all the way up to 300. The company Xvivo makes machines and solutions for preserving organs during transplantation, and the business is actually running strong. In Q2, organic growth was 36%, and sales in thorax increased 53%. Over 600 patients have now been transplanted with their heart technology, and in Australia it is already used for approx. 40% of heart transplantations. The big hurdle is the approval of the heart product, especially in the US, where most of the investments go to precisely that process. If it gets through, it is a significant game changer for the company. Next financial report comes on October 22, and we will hear how far they are with the approvals. My setup Price now: approx. 213 Support: the ascending trend line, approx. 205-210 1st target: approx. 245 = approx. +15% 2nd target: approx. 285 = approx. +34% Longer term: the top line around 315 = approx. +48% Next major event: the Q3 report on October 22 If the support is broken: if we close below the line on a weekly basis, the triangle is broken downwards, and then you should not stand around hoping. If the support holds up towards the report, I think risk/reward looks really exciting. It is a medtech stock, so the report and news about approvals can give large fluctuations both ways. REMEMBER: The Q3 report on October 22 This is not investment advice, but my own technical assessment. Always do your own analysis.
- ·1.10.Will the CEO's positive outlook on underlying growth from the Q2 report be scrutinized in Q3, which is released on 22/10? And have orders started being placed since the CE cert. for heart preservation technology on 11/8? If these points are met, I believe Xvivo will enter a strong period. What are your thoughts/perceptions on the near future?I have just increased by 250 pcs more (50% extra) so am lying with 750 GAK 185 - so now it is welcome to go towards 300-400 pieces :-). Hope Danske has right about a strong Q3
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä |
|---|---|---|
| 24 | ||
| 12 | ||
| 21 | ||
| 128 | ||
| 54 |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
NimiOsuus
Evli Ruotsi Pienyhtiöt B
2,79%Asiakkaat katsoivat myös
Välittäjätilasto
Dataa ei löytynyt